See more : RocTool S.A. (ALROC.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- JILIN JINGUAN ELECTRIC Co.,Ltd (300510.SZ) Income Statement Analysis – Financial Results
- StartEngine Crowdfunding, Inc. (STGC) Income Statement Analysis – Financial Results
- MedAvail Holdings, Inc. (MDVLQ) Income Statement Analysis – Financial Results
- MRS Logística S.A. (MRSA6B.SA) Income Statement Analysis – Financial Results
- Pernod Ricard SA (RI.SW) Income Statement Analysis – Financial Results
Monopar Therapeutics Inc. (MNPR)
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 15.44M | 280.36K | 101.49K |
| General & Administrative | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Selling & Marketing | -3.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.50M | 0.00 | 0.00 |
| Operating Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Cost & Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Interest Income | 429.04M | 21.24K | 24.02K | 81.90K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.22K | 48.26K | 7.23K | 0.00 |
| Depreciation & Amortization | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.33M | 2.10M | 1.19M | 688.56K |
| EBITDA | 429.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.55M | 8.03K | 1.25K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.40M | -16.60M | -1.19M | -688.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 429.04K | 21.24K | 24.02K | 204.30K | 98.89K | 31.15K | 48.26K | 8.03K | 1.25K |
| Income Before Tax | -8.40M | -10.52M | -9.10M | -6.30M | -4.22M | -3.30M | -16.55M | -1.19M | -687.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -21.24K | -24.02K | -81.90K | -98.89K | -71.62K | -2.10M | 800.00 | -688.56K |
| Net Income | -8.40M | -10.49M | -9.08M | -6.22M | -4.13M | -3.23M | -16.55M | -1.19M | -687.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| EPS Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| Weighted Avg Shares Out | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
| Weighted Avg Shares Out (Dil) | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients
Source: https://incomestatements.info
Category: Stock Reports